Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease:clinical outcomes in real-world patients from the DANBIO registry

Autor: Hafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Kristian Pedersen, Søren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Høger Thygesen, Louise Brot Christensen, Maren Høgberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg

Publikováno v: Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, e002560 . https://doi.org/10.1136/rmdopen-2022-002560
Nabi, H, Hetland, M L, Loft, A G, Hendricks, O, Jensen, D, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Grydehøj, J, Raun, J, Ahmed, R, Mehnert, F, Krogh, N S & Glintborg, B 2022, ' INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY ', Annals of the Rheumatic Diseases, vol. 81, no. Suppl. 1, OP0065, pp. 45-46 . https://doi.org/10.1136/annrheumdis-2022-eular.2306
Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560
Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560

ObjectiveSuccessful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bcafac3b27cbee58119c12faba1e028
https://vbn.aau.dk/da/publications/1224b0b0-ee61-4f51-a117-2bb3d48fd527